{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:58:07Z","timestamp":1753876687198,"version":"3.41.2"},"reference-count":18,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>This case report is about a 51-year-old active duty male with JAK2 mutation and medical history significant for prehepatic portal hypertension from portal vein thrombus on lifelong anticoagulation with rivaroxaban, an oral factor Xa inhibitor, presenting with closed-loop small bowel obstruction requiring emergent laparotomy. We present this surgical case as it required emergent reversal of the oral factor Xa inhibitor with andexanet\u00a0alfa.<\/jats:p>","DOI":"10.1093\/milmed\/usab151","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T21:41:18Z","timestamp":1619127678000},"source":"Crossref","is-referenced-by-count":0,"title":["Andexanet Alfa Use for Small Bowel Obstruction Patient With History of Sugiura Procedure"],"prefix":"10.1093","author":[{"given":"Adam K","family":"Brust","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Naval Medical Center, San Diego, CA 92134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarateedha P","family":"LeCourt","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Naval Medical Center, San Diego, CA 92134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek A","family":"Benham","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Naval Medical Center, San Diego, CA 92134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan R","family":"Gower","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Naval Medical Center, San Diego, CA 92134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean D","family":"Birmingham","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Naval Medical Center, San Diego, CA 92134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"6","key":"2021042208042292800_R1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"key":"2021042208042292800_R2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.yasu.2019.04.011","article-title":"Anticoagulants and surgery: so many agents, so many taking them","volume":"53","author":"Patel","year":"2019","journal-title":"Adv Surg"},{"issue":"10","key":"2021042208042292800_R3","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J Clin Invest"},{"issue":"25","key":"2021042208042292800_R4","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet\u00a0alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2021042208042292800_R5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tcm.2019.03.004","article-title":"A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery","volume":"30","author":"Milling","year":"2020","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"2021042208042292800_R6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2021042208042292800_R7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-11-11","article-title":"Laboratory assessment of rivaroxaban: a review","volume":"11","author":"Samama","year":"2013","journal-title":"Thromb J"},{"issue":"12","key":"2021042208042292800_R8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2021042208042292800_R9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2021042208042292800_R10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2021042208042292800_R11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrcardio.2017.223","article-title":"Reversal agents for non-Vitamin K antagonist oral anticoagulants","volume":"15","author":"Levy","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"2021042208042292800_R12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet\u00a0alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2021042208042292800_R13","article-title":"Direct-acting oral anticoagulants and their reversal agents\u2014an update","volume":"6","author":"Kustos","year":"2019","journal-title":"Medicines"},{"issue":"2","key":"2021042208042292800_R14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/HPC.0000000000000177","article-title":"Andexanet\u00a0alfa (Andexxa) formulary review","volume":"18","author":"Beik","year":"2019","journal-title":"Crit Pathw Cardiol"},{"issue":"10","key":"2021042208042292800_R15","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1002\/ajh.25587","article-title":"Coordinating emergent procedures after andexanet\u00a0alfa","volume":"94","author":"Culbreth","year":"2019","journal-title":"Am J Hematol"},{"issue":"10","key":"2021042208042292800_R16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-018-0940-4","article-title":"Andexanet\u00a0alfa: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"issue":"15","key":"2021042208042292800_R17","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2021042208042292800_R18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1213\/XAA.0000000000001052","article-title":"Andexanet\u00a0alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass","volume":"13","author":"Flaherty","year":"2019","journal-title":"A&A Pract"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/advance-article-pdf\/doi\/10.1093\/milmed\/usab151\/37251116\/usab151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/advance-article-pdf\/doi\/10.1093\/milmed\/usab151\/37251116\/usab151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T21:41:40Z","timestamp":1619127700000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/advance-article\/doi\/10.1093\/milmed\/usab151\/6245265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":18,"URL":"https:\/\/doi.org\/10.1093\/milmed\/usab151","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"type":"print","value":"0026-4075"},{"type":"electronic","value":"1930-613X"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"article-number":"usab151"}}